News
Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...
The interplay between sex and serious bacterial infections, including bacteremia and sepsis, is complex and more research is ...
The Sabin Vaccine Institute has begun a trial to evaluate its Marburg vaccine, with the first doses being given to subjects ...
Viral hepatitis was the most common cause of infectious disease mortality worldwide after tuberculosis in 2024, according to ...
The World Health Organization (WHO) has released an update on polio following the March 2025 meeting of the International ...
The EMA has approved Cullinan Therapeutics’ clinical trial application for CLN-978, a drug intended to treat rheumatoid ...
More than just a tool for advancing pipelines, trial efficiency is the name of the game when it comes to synthetic control ...
Hoth Therapeutics has reported interim data from a trial of HT-001, a drug designed for treating pruritus associated with ...
Accent Therapeutics has dosed the first subject in an open-label Phase I/II trial of ATX-295, an oral kinesin family member ...
Genesis has gained US Food and Drug Administration (FDA) clearance on an Investigational New Drug (IND) application for a ...
An independent Data Safety Monitoring Board (DSMB) has recommended the continuation of BioCardia's Phase I/II CardiALLO-HF ...
Long Covid remains poorly understood and follow-up studies play an integral role in establishing an epidemiological and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results